Rathbones Group PLC Has $229,000 Position in ImmunityBio, Inc. (NASDAQ:IBRX)

Rathbones Group PLC raised its stake in ImmunityBio, Inc. (NASDAQ:IBRX) by 21.8% during the 4th quarter, Holdings Channel.com reports. The firm owned 89,420 shares of the company’s stock after buying an additional 16,000 shares during the period. Rathbones Group PLC’s holdings in ImmunityBio were worth $229,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Stephens Inc. AR acquired a new position in shares of ImmunityBio in the fourth quarter valued at about $26,000. Cibc World Markets Corp acquired a new position in shares of ImmunityBio in the fourth quarter valued at about $35,000. Maia Wealth LLC acquired a new position in shares of ImmunityBio in the fourth quarter valued at about $37,000. Schechter Investment Advisors LLC acquired a new position in shares of ImmunityBio in the fourth quarter valued at about $38,000. Finally, Crestwood Advisors Group LLC acquired a new position in shares of ImmunityBio in the fourth quarter valued at about $41,000. 8.58% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $8.00 price objective on shares of ImmunityBio in a research note on Thursday, March 13th. D. Boral Capital reiterated a “buy” rating and set a $30.00 price objective on shares of ImmunityBio in a research note on Wednesday. Finally, BTIG Research assumed coverage on shares of ImmunityBio in a research note on Friday, January 10th. They set a “buy” rating and a $6.00 price objective on the stock. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, ImmunityBio presently has an average rating of “Buy” and a consensus price target of $12.19.

ImmunityBio Stock Performance

NASDAQ:IBRX opened at $2.60 on Thursday. The business has a 50 day moving average price of $3.04 and a 200-day moving average price of $3.55. ImmunityBio, Inc. has a fifty-two week low of $2.28 and a fifty-two week high of $10.53. The firm has a market cap of $2.22 billion, a PE ratio of -2.83 and a beta of 0.51.

ImmunityBio (NASDAQ:IBRX) last announced its quarterly earnings results on Monday, March 3rd. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.11. The business had revenue of $7.55 million during the quarter, compared to analysts’ expectations of $8.74 million. Research analysts predict that ImmunityBio, Inc. will post -0.92 EPS for the current year.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.